Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

已完结 10 由小花花发布于 2025/9/9 9:04:06

DOI:10.1016/s0140-6736(24)01808-7
作者：Domenica Lorusso,Yang Xiang,Kosei Hasegawa,Giovanni Scambia,Manuel Leiva,Pier Ramos-Elias,Alejandro Acevedo,Jakub Cvek,Leslie Randall,Andrea Juliana Pereira de Santana Gomes,Fernando Contreras Mejía,
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BACKGROUND At the first interim analysis of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, the addition of pembrolizumab to chemoradiotherapy provided a statistically significant and cl

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierHuman key point detection method based on enhanced receptive field and transformer